NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Ocular Therapeutix, Inc. (“Ocular Therapeutix”) (NASDAQ: OCUL) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/OCUL-Info-Request-Form-1645. There is no cost or obligation to you.
On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant. However, on July 6, 2017, an article published by Seeking Alpha claimed that Ocular Therapeutix’s management had been misleading investors about manufacturing issues. One of the claims made by the article is that more than 50% of lots manufactured by Ocular Therapeutix contain bad product. Following this news, the price of Ocular Therapeutix shares fell $0.68 per share or over 6% to close at $9.50 per share on July 6, 2017.
To learn more about the investigation of Ocular Therapeutix contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/OCUL-Info-Request-Form-1645.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.